Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

Inclusion Criteria: * Refractive error by cycloplegic autorefraction: myopia -1.00 D to -6.00 D in both eyes; astigmatism ≤ 1.50 D in both eyes; anisometropia \< 1.50 D. * Best-corrected distance visual acuity in current correction of 0.2 logMAR or better with interocular difference ≤ 0.1 logMAR. * Refractive correction for each eye meets the following criteria: myopia within ± 0.50 D of the manifest refraction at the Screening Visit; cylinder power within ± 0.50 D of the manifest refraction at the Screening Visit; when cylinder power is \< 1.00 D, axis within ± 15 degrees of the manifest refraction; when cylinder power is ≥ 1.00 D, axis within ± 5 degrees of the manifest refraction. Exclusion Criteria: * Current or previous myopia treatment with non-study atropine, pirenzepine or other topical anti-muscarinic agent. * Current use of bifocals, progressive-addition lenses, or multifocal soft contact lenses. * Use of rigid gas permeable lenses, including orthokeratology lenses within 90 days of Screening. * Known atropine allergy. * Abnormality of the cornea, lens, central retina, iris or ciliary body. * Current or prior history of manifest strabismus, amblyopia, or nystagmus. * Prior eyelid, strabismus, intraocular, or refractive surgery. * Intraocular pressure \> 26 mmHg. * History of premature birth by parent's report. * Inability to perform protocol-prescribed testing due to preexisting neurological diagnoses, genetic syndrome, or other issues. * Medical conditions predisposing patient to degenerative myopia, abnormal ocular refractive anatomy, and/or any history of intraocular surgery. * Any systemic disease or condition that may affect visual function or development such as diabetes mellitus. * Any ocular inflammation or external ocular inflammation within 30 days of Screening. * History of punctal occlusion. * Heterochromia. * Lid squeezers. * Participation in any study of an investigational, interventional product within 30 days prior to Screening Visit. * Immediate family member of study staff designed to perform study evaluations or procedures. * Pregnancy, or if sexually active, unwillingness to use an acceptable form of contraception during the study. * Presence of a severe/serious ocular condition or any other unstable medical condition that, in the Investigator's opinion, may preclude study treatment or follow-up.